Robert “Bob” Cashman has been promoted to vice president of business development at OSO BioPharmaceuticals Manufacturing. In his new role, Mr. Cashman is responsible for developing and executing strategies to expand the company’s injectable pharmaceutical contract manufacturing business. He also will oversee existing and potential customer relationships, manage pricing structures, and direct strategic alliances.
Mr. Cashman joined OsoBio in 2009, and previously served as director of new business development for the company’s East Coast market. Mr. Cashman has more than 20 years of experience in contract pharmaceutical and biotechnology manufacturing. He serves a board member of the Philadelphia Drug Exchange and a member of the Parenteral Drug Association. He also heads the scholarship committee for the Drug, Chemical and Associated Technologies Association (DCAT).
“Bob has consistently demonstrated a keen ability to foster existing and new client
opportunities for OsoBio,” said Milton Boyer president of OsoBio. “As OsoBio continues to successfully grow as a CMO renowned for world-class customer care, project management and regulatory compliance, I know Bob will help us achieve the goals we’ve set for ourselves.”